Talus Bio

📍 Seattle, United States🗓 Founded 2020👥 26 employees💰 Last funded Jul 2024
Biotechnology Research🌐 talus.bio
Website LinkedIn
Talus Bio is making the regulome visible and druggable. We are building the first platform to map, model, and ultimately write the regulome, unlocking thousands of previously undruggable targets, including transcription factors that drive cancer, autoimmunity, and neurodegeneration. Our platform measures the regulome directly in living human cells, generating functional datasets at scale for the first time. These data fuel AI models that learn the logic of genome regulation and predict how to modulate it with precision.
4
Total investors
2
Early stage
2
Mid stage
0
Late stage
2020
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
4
Investor activity2021–2024 · investors recorded per year
202122023120241
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Talus Bio?
Talus Bio has 4 investors on record on gritt.io, including 2 early-stage backers, 2 mid-stage.
When did Talus Bio last raise funding?
The most recent investment in Talus Bio recorded on gritt.io was in July 2024.
When was Talus Bio founded?
Talus Bio was founded in 2020.
What industry is Talus Bio in?
Talus Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Talus Bio based?
Talus Bio is headquartered in Seattle, United States.